On August 5, 2026, Hong Kong-listed BioSino Bio-Tec and Science Inc (08247.HK) announced a two-step plan to acquire a combined 70.3% stake in Shanghai Jiangcu Technology Co., Ltd. The deal involves a 10% purchase of existing shares followed by a 67% cash injection into new shares, totaling approximately 164 million yuan. This includes 7.7 million yuan paid via the issuance of about 2.79 million H-shares at 3.2 Hong Kong dollars each, with the remaining 156 million yuan in cash used to subscribe for new registered capital. After the capital increase, Shanghai Jiangcu's registered capital will rise from 1 million yuan to 3.03 million yuan. Upon completion, Shanghai Jiangcu will become a non-wholly owned subsidiary of BioSino, with its financial results consolidated into the group's accounts.

The cost of this integration is steep: BioSino is paying a sum equivalent to nearly 90% of its 2025 annual revenue and about 80% of its current market capitalization to acquire a scientific reagent distributor founded just 15 years ago. Shanghai Jiangcu, established in 2011, focuses on the R&D, sales, and technical services of scientific instruments, biological reagents, IVD products, and upstream core raw materials and lab consumables. Its core business includes the authorized distribution of Promega's NanoLuc® mRNA in China, along with the academic promotion and distribution of the OncoMate® Microsatellite Instability solid tumor companion diagnostic product.

According to the announcement, Shanghai Jiangcu's audited net profit for 2025 was 110.5 million yuan. Based on the 164 million yuan acquisition of a 70.3% stake, the target's overall valuation is about 233 million yuan, translating to a price-to-earnings (P/E) ratio of roughly 2.1 times based on 2025 net profit. From a static P/E perspective, the deal appears inexpensive. However, the issue lies in the valuation methodology. The transaction used an income approach for evaluation, setting the target's value at 77 million yuan. Yet, the effective price of 233 million yuan implies a roughly threefold gap between the income-based valuation and the actual transaction pricing. The deal's anchor is not the income approach result itself but the future profit expectations underpinning it.

The core logic of the income approach is "pricing based on discounted future cash flows," not on net assets or historical profits. The announcement shows the target company has a low net asset base (registered capital of just 1 million yuan), resulting in an extraordinary 405.21% appreciation rate from the income method. In M&A, such a high appreciation rate typically points to two possibilities: the target possesses intangible assets not reflected on its books, such as exclusive distribution rights, customer relationships, or technical barriers; or the future profit forecasts used in the valuation are overly optimistic, leading to a high discounted value. Shanghai Jiangcu's "intangible assets" do exist, including the exclusive Chinese distribution rights for Promega's NanoLuc® mRNA and the academic promotion channels for the OncoMate® MSI companion diagnostic. Promega is a globally renowned life science reagent supplier, making its exclusive agency rights quite scarce. Additionally, Shanghai Jiangcu has built a customer network across universities, research institutes, medical institutions, and biopharmaceutical companies over a decade. However, the value of exclusive rights depends on the stability and renewal terms of the agency agreement and the growth potential of downstream demand. If the rights expire without renewal, or if Promega adjusts its China strategy and reclaims the agency, the target's core value would be significantly diminished.

To support this high valuation, the original shareholders made a performance commitment: net profit must grow by no less than 20% annually from 2026 to 2028. Based on the 2025 net profit of 110.5 million yuan, the 20% annual growth implies: 2026 net profit of at least 132.6 million yuan, 2027 of at least 159.1 million yuan, and 2028 of at least 190.9 million yuan. The cumulative committed net profit over three years is about 483 million yuan. For a company primarily engaged in scientific reagent distribution and companion diagnostic promotion, maintaining over 20% net profit growth for three consecutive years is challenging in the current biomedical industry environment. The growth of the scientific reagent distribution business is constrained by the budget cycles of universities and research institutes, while the promotion of companion diagnostics faces intense market competition and pressure from medical insurance cost containment. If the performance commitments are not met, the original shareholders must compensate under the agreement—but the actual enforcement of the compensation mechanism and whether the amount would cover the listed company's valuation losses remains uncertain.

The transaction faces at least three major tests. First, integration risk. A listed company focused on clinical IVD is acquiring a target centered on scientific reagent distribution. Their customer bases (medical institutions vs. university research institutes), business models (clinical testing vs. scientific services), and operational logics differ significantly. The ability to achieve the expected synergies during integration is highly uncertain. Second, the risk of fulfilling performance commitments. Sustaining 20% net profit growth for three consecutive years is an aggressive target for a distribution company. If downstream research funding contracts, competition in the companion diagnostic market intensifies, or agency agreements change, meeting the commitments will be difficult. Third, financial pressure. BioSino's 2025 revenue was only 184 million yuan, with a net loss attributable to the parent of 51.142 million yuan. The 156 million yuan cash injection is a heavy burden for a company with annual revenue under 200 million yuan and persistent losses, further compressing its liquidity.

In conclusion, BioSino's chairman, Chen Peng, stated that this acquisition marks "a new beginning for the deep integration of scientific research capabilities with clinical industry." However, whether this "beginning" leads to the expected outcome depends on three key variables: whether the performance commitments are met, whether integration synergies materialize, and whether post-acquisition cash flow supports the business fusion. The answers lie not in the announcement but in the financial statements of the next three years.